Abiopharma

ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference

FDA Grants Priority Review for KEYTRUDA®(pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer

HALEON PLC (HLN) Files Form 6-K

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer

(30% Negative) CLEVELAND-CLIFFS INC. (CLF) Reports Q2 2026 Financial Results

(99% Neutral) SUTTER GOLD MINING INC. (USGO) Files Form 8-K

(100% Positive) THERMON GROUP HOLDINGS, INC. (THR) Announces Business Combination

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Virgin Galactic Reports Inducement Award Under NYSE Listing Rule 303A.08

U.S. FDA Grants Priority Review to sBLA for PADCEV + Keytruda as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Bank of Hawai‘i Corporation First Quarter 2026 Financial Results

Spire Global Selected by Precursor SPC to Support Hypersonic Tracking

Pediatrix Medical Group 2026 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 5, 2026

SOLAI Limited Files 2025 Annual Report on Form 20-F